| Popis: |
Nabil Belfeki, Sarra Hamrouni, Alessio Strazzulla, Sylvain Diamantis Department of Internal Medicine, Groupe Hospitalier Sud-Ile de France, Melun, 77000, FranceCorrespondence: Nabil BelfekiDepartment of Internal Medicine, Groupe Hospitalier Sud Ile de France, 77000, Melun Tel +33 1 81 74 17 04Fax +33 1 81 74 18 12Email belfeki.nabil@gmail.comAbstract: Acquired hemophilia is a rare coagulopathy with hemorrhage into the skin, muscle, or soft tissues and mucous membranes and caused by inhibitor antibodies, mainly against FVIII. We report a case of acquired hemophilia presenting with diffuse cutaneous hemorrhage and hemothorax. The patient was found to have acquired an FVIII inhibitor and a high titer of anti β 2 glycoprotein 1 IgG and IgM, and anticardiolipin IgM in the context of IgA kappa-type monoclonal gammopathy. He received 3 injections of recombinant factor VII (rFVIIa) and blood transfusion. He was started on steroids and oral cyclophosphamide for 6 weeks. Thromboprophylaxis with aspirin at 100 mg/day was started 3 months after discharge. Antiphospholipid antibodies remained positive after 3 months as well as prolonged aPTT, factor VIII raised at 100%, and the inhibitor was not detected. The association between acquired hemophilia and antiphospholipid antibodies is rare and its distinction is mandatory because clinical presentation ranges from massive hemorrhage to thrombosis.Keywords: acquired hemophilia, factor VIII deficiency, antiphospholipid antibodies, hemorrhage, treatment |
